Metavia Inc. · NASDAQ:MTVA
Metavia — NeuroBo Pharmaceuticals — Investor Presentation (April 2024)
27 slides from Metavia's investor presentation, Apr 16, 2024
Slide 1: NeuroBo Pharmaceuticals, Inc.
December 2023 NASDAQ: NRBO 1 April 2024 NeuroBo Pharmaceuticals, Inc.
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the us
Slide 3: Strong Leadership Team
3 Strong Leadership Team Management Team Hyung Heon Kim, Chief Executive Officer Robert Homolka, SVP Clinical Operations Stephen Harrison, M.D., Consulting Chief Medical Officer Mi-Kyung Kim, Ph.D., RPh, Chief Scientific Officer Marshall H. Woodworth, Chief Financial Officer ▪ 20+ years of experienc
Slide 4: Compelling Investment Opportunity Targeting Obesity and MASH with a Pipeline of Next Generation Therapeutics
4 Compelling Investment Opportunity Targeting Obesity and MASH with a Pipeline of Next Generation Therapeutics ▪ Aiming to Increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones • DA-1726 ✓Open IND for Treatment of Obesity ✓First patient dosed and actively recruiting into
Slide 5: Pipeline
5 Pipeline Asset Preclinical Phase 1 Phase 2 DA-1241 (GPR119 Agonist) DA-1726 (GLP1R/GCGR Dual Agonist) 2a 2b OBESITY Indication MASH Obesity
Slide 6: Multiple Near-Term Milestones: Targeting to Increase Shareholder Value
6 Multiple Near-Term Milestones: Targeting to Increase Shareholder Value Investments in the current DA-1241 Phase 2a and DA-1726 Phase 1 have the potential for significant returns in the event of clinical and regulatory success Q1/Q2 2025 Meeting with FDA 2024 2025 DA-1241 Q3 2024 Phase 2a Last Pati
Slide 7: DA-1726: Upcoming Phase 1 Part 3 Trial in Obesity Timeline
7 DA-1726: Upcoming Phase 1 Part 3 Trial in Obesity Timeline Phase 1 Part 3 will assess total weight loss at 24 weeks, exploring maximum titratable dose and dietary changes. 2025 2026 DA-1726 Part 3 H1 2026 Part 3 Last Patient Visit Q3 2025 Part 3 First Patient Dosed H2 2026 Part 3 Top Line Results
Slide 8: DA-1726: Upcoming Phase 1 Part 3 to Evaluate Maximum Titratable Dose Study Design
8 DA-1726: Upcoming Phase 1 Part 3 to Evaluate Maximum Titratable Dose Study Design Study Overview ▪ A multicenter, randomized, double-blind, placebo-controlled, Phase 1 clinical trial to evaluate the efficacy and safety of DA-1726 in obese, otherwise healthy subjects Additional Endpoints ▪ Biomarke
Slide 9: DA-1726 A Novel GLP1R/GCGR Dual Agonist for the Treatment of Obesity
December 2023 NASDAQ: NRBO 9 DA -1726 A Novel GLP1R/GCGR Dual Agonist for the Treatment of Obesity
Slide 10: DA-1726: Competitive Differentiation
10 DA-1726: Competitive Differentiation Survodutide Mazdutide DA-1726 Semaglutide Tirzepatide Developer Boehringer Ingelheim Innovent Biologics Lilly NeuroBo Novo Nordisk Lilly Indication Obesity Obesity Obesity Obesity Obesity Status Phase 2 completed Phase 3 (China) Phase 1 (USA) Phase 1 Marketed
Slide 11: DA-1726: Mechanism of Action
11 DA-1726: Mechanism of Action DA-1726 is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/Glucagon Receptor); GLP-1 (Glucagon-Like Peptide 1) 1. Pocai A. Mol Metab.2014;3:241-51 ▪ Oxyntomodulin
Slide 12: DA-1726: Therapeutic Potential in Obesity — Semaglutide Comparison
12 DA-1726: Therapeutic Potential in Obesity(1-3) — Semaglutide Comparison DA-1726 outperformed Semaglutide (WEGOVY ), a GLP-1 agonist, in mouse models of obesity* *Statistically significant compared to control Notes: GLP1R/GCGR (Glucagon-Like Peptide 1 Receptor/ Glucagon Receptor); HF-DIO (High Fat
Slide 13: DA-1726: Therapeutic Potential in Obesity — Tirzepatide Comparison
13 DA-1726: Therapeutic Potential in Obesity (1,2) — Tirzepatide Comparison DA-1726 shows similar weight loss while consuming more food compared to Tirzepatide (Mounjaro ) Notes: HF-DIO (High Fat-Diet Induced Obesity); BWL (Body Weight Loss) 1. Dong-A Study Report 105497. All treatments given as twi
Slide 14: DA-1726: Phase 1 Part 1 & 2 to Evaluate Safety and Tolerability
14 DA-1726: Phase 1 Part 1 & 2 to Evaluate Safety and Tolerability Rationale for study ▪ Gain a robust understanding of safety, tolerability of various dose levels in humans. ▪ Superior weight loss compared with the pair-fed group, indicating much of the weight loss was attributed to reduced food in
Slide 15: DA-1726: Upcoming Phase 1 Part 3 to Evaluate Maximum Titratable Dose Study Design
15 DA-1726: Upcoming Phase 1 Part 3 to Evaluate Maximum Titratable Dose Study Design Study Overview ▪ A multicenter, randomized, double-blind, placebo-controlled, Phase 1 clinical trial to evaluate the efficacy and safety of DA-1726 in obese, otherwise healthy subjects Additional Endpoints ▪ Biomark
Slide 16: DA-1241 Orally Available, Potential First-in-Class GPR119 Agonist for the Treatment of MASH
December 2023 NASDAQ: NRBO 16 DA-1241 Orally Available, Potential First-in-Class GPR119 Agonist for the Treatment of MASH
Slide 17: DA-1241: Competitive Differentiation
17 DA-1241: Competitive Differentiation 1. https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3 Resmetirom DA-1241 Developer Madrigal NeuroBo Indication MASH MASH Status Phase 3 completed NDA Submitted Phase 2 Action THR (Thyroi
Slide 18: DA-1241 Effect on Pathogenesis in MASH as a Monotherapy
18 DA-1241 Effect on Pathogenesis in MASH as a Monotherapy GPR119 activation: Monocytes and macrophages ▪ Macrophage activation ▪ Monocyte recruitment ▪ Macrophage differentiation → Reduction in hepatic and systemic inflammation Hepatic stellate cells Stellate cell activation → Reduce hepatic fibrog
Slide 19: GPR119 in Glucose Control when Co-Administered with Other Therapies
19 GPR119 in Glucose Control when Co-Administered with Other Therapies ▪ Effectively decreased hepatic inflammation ▪ Reduced systemic inflammation and fibrosis biomarkers ▪ Reduced hepatic lipid and collagen deposition in the liver of MASH mice Activation of GLP1 Receptor Effects ▪ Pancreas • Incre
Slide 20: DA-1241: Ongoing Phase 2a in MASH Support use as a monotherapy
20 DA-1241: Ongoing Phase 2a in MASH Support use as a monotherapy Study Design Study Overview ▪ A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA-1241 in subjects with presumed non-alcoholic steatohepatitis Primar
Slide 21: Financials and Capitalization
December 2023 NASDAQ: NRBO 21 Financials and Capitalization
Slide 22: Cash Balance and Capitalization Table
22 Cash Balance and Capitalization Table Cash Balance As of December 31, 2023 Cash $22.4 million Debt none Capitalization Table as of December 31, 2023 Common Stock Equivalents Common Stock (as of March 31, 2024) 4,906,032 Warrants (WAEP $145.54)(1) 203,914 Options (WAEP $398.30) 4,700 Common Stock
Slide 23: Multiple Near-Term Milestones: Targeting to Increase Shareholder Value
23 Multiple Near-Term Milestones: Targeting to Increase Shareholder Value Investments in the current DA-1241 Phase 2a and DA-1726 Phase 1 have the potential for significant returns in the event of clinical and regulatory success Q1/Q2 2025 Meeting with FDA 2024 2025 DA-1241 Q3 2024 Phase 2a Last Pat
Slide 24: DA-1726: Upcoming Phase 1 Part 3 Trial in Obesity Timeline
24 DA-1726: Upcoming Phase 1 Part 3 Trial in Obesity Timeline Phase 1 Part 3 will assess total weight loss at 24 weeks, exploring maximum titratable dose and dietary changes. 2025 2026 DA-1726 Part 3 H1 2026 Part 3 Last Patient Visit Q3 2025 Part 3 First Patient Dosed H2 2026 Part 3 Top Line Results
Slide 25: Investment Thesis
December 2023 NASDAQ: NRBO 25 Investment Thesis
Slide 26: Compelling Investment Opportunity Targeting Obesity and MASH with a Pipeline of Next Generation Therapeutics
26 Compelling Investment Opportunity Targeting Obesity and MASH with a Pipeline of Next Generation Therapeutics ▪ Aiming to Increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones • DA-1726 ✓Open IND for Treatment of Obesity ✓First patient dosed and actively recruiting into
Slide 27: Thank You!
December 2023 NASDAQ: NRBO 27 Thank You! Investor Contacts: Rx Communications Group Michael Miller +1 917.633.6086 mmiller@rxir.com NeuroBo Pharmaceuticals Marshall Woodworth +1 919.749.8748 marshall.woodworth@neurobopharma.com
NeuroBo Pharmaceuticals — Investor Presentation (April 2024) on 6ix